In vivo in a xenograft model the treatment with functionalized NP significantly reduced the tumor volume and in an orthotopic model using U-87 MG cells the NPs increased the therapeutic effect of PTX and accumulated at the tumor site, increasing the median survival time showing the potential to target the transferrin receptor in the treatment of GBM [159]. The gene discussed is TFRC; the disease is neoplasm.